{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T21:26:50Z","timestamp":1773437210250,"version":"3.50.1"},"reference-count":26,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,9,13]],"date-time":"2021-09-13T00:00:00Z","timestamp":1631491200000},"content-version":"am","delay-in-days":347,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Oncology: Seminars and Original Investigations"],"published-print":{"date-parts":[[2020,10]]},"DOI":"10.1016\/j.urolonc.2020.07.020","type":"journal-article","created":{"date-parts":[[2020,8,7]],"date-time":"2020-08-07T08:28:05Z","timestamp":1596788885000},"page":"797.e15-797.e20","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Repeat ablative therapy in hereditary or multifocal renal cancer: Functional and oncological outcomes"],"prefix":"10.1016","volume":"38","author":[{"given":"Victor","family":"Gaillard","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thibault","family":"Tricard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julien","family":"Garnon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberto Luigi","family":"Cazzato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Danoob","family":"Dalili","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Afshin","family":"Gangi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Herve","family":"Lang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.urolonc.2020.07.020_bib0001","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1200\/JCO.2013.50.8192","article-title":"Defining early-onset kidney cancer: implications for germline and somatic mutation testing and clinical management","volume":"32","author":"Shuch","year":"2014","journal-title":"J Clin Oncol."},{"issue":"12","key":"10.1016\/j.urolonc.2020.07.020_bib0002","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1097\/PAS.0000000000000562","article-title":"Hereditary renal cell carcinoma syndromes: clinical, pathologic, and genetic features","volume":"39","author":"Adeniran","year":"2015","journal-title":"Am J Surg Pathol"},{"issue":"9374","key":"10.1016\/j.urolonc.2020.07.020_bib0003","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1016\/S0140-6736(03)13643-4","article-title":"von Hippel-Lindau disease","volume":"361","author":"Lonser","year":"2003","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.urolonc.2020.07.020_bib0004","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/j.crad.2008.10.010","article-title":"Radiological evaluation, management, and surveillance of renal masses in Von Hippel\u2013Lindau disease","volume":"64","author":"Meister","year":"2009","journal-title":"Clin Radiol"},{"issue":"5","key":"10.1016\/j.urolonc.2020.07.020_bib0005","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1016\/j.eururo.2015.01.005","article-title":"EAU guidelines on renal cell carcinoma: 2014 update","volume":"67","author":"Ljungberg","year":"2015","journal-title":"Eur Urol"},{"issue":"3","key":"10.1016\/j.urolonc.2020.07.020_bib0006","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/j.juro.2017.04.100","article-title":"Renal mass and localized renal cancer: AUA guideline","volume":"198","author":"Campbell","year":"2017","journal-title":"J Urol"},{"issue":"1","key":"10.1016\/j.urolonc.2020.07.020_bib0007","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1097\/01.ju.0000132127.79974.3f","article-title":"The relationship between renal tumor size and metastases in patients with Von Hippel-Lindau disease","volume":"172","author":"Duffey","year":"2004","journal-title":"J Urol"},{"issue":"12","key":"10.1016\/j.urolonc.2020.07.020_bib0008","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1007\/s00345-018-2288-5","article-title":"Hereditary renal cell carcinoma syndromes: diagnosis, surveillance and management","volume":"36","author":"Maher","year":"2018","journal-title":"World J Urol"},{"issue":"5","key":"10.1016\/j.urolonc.2020.07.020_bib0009","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1016\/S0022-5347(05)68930-6","article-title":"Renal cancer in families with hereditary renal cancer: prospective analysis of a tumor threshold for renal parenchymal sparing surgery","volume":"161","author":"Walther","year":"1999","journal-title":"J Urol"},{"issue":"3","key":"10.1016\/j.urolonc.2020.07.020_bib0010","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1007\/s00270-012-0470-5","article-title":"Determination of the nonlethal margin inside the visible \u201cice-ball\u201d during percutaneous cryoablation of renal tissue","volume":"36","author":"Georgiades","year":"2013","journal-title":"Cardiovasc Intervent Radiol"},{"issue":"3","key":"10.1016\/j.urolonc.2020.07.020_bib0011","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1006\/cryo.1998.2115","article-title":"Mechanisms of tissue injury in cryosurgery","volume":"37","author":"Gage","year":"1998","journal-title":"Cryobiology"},{"issue":"3","key":"10.1016\/j.urolonc.2020.07.020_bib0012","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.cryobiol.2007.07.003","article-title":"Cryosurgical technique: assessment of the fundamental variables using human prostate cancer model systems","volume":"55","author":"Klossner","year":"2007","journal-title":"Cryobiology"},{"issue":"3","key":"10.1016\/j.urolonc.2020.07.020_bib0013","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1016\/j.juro.2009.05.035","article-title":"The R.E.N.A.L. nephrometry score: a comprehensive standardized system for quantitating renal tumor size, location and depth","volume":"182","author":"Kutikov","year":"2009","journal-title":"J Urol"},{"issue":"2","key":"10.1016\/j.urolonc.2020.07.020_bib0014","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1097\/01.sla.0000133083.54934.ae","article-title":"Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey","volume":"240","author":"Dindo","year":"2004","journal-title":"Ann Surg"},{"issue":"4","key":"10.1016\/j.urolonc.2020.07.020_bib0015","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.eururo.2010.12.013","article-title":"A prospective, randomised EORTC intergroup phase 3 study comparing the oncologic outcome of elective nephron-sparing surgery and radical nephrectomy for low-stage renal cell carcinoma","volume":"59","author":"Van Poppel","year":"2011","journal-title":"Eur Urol"},{"issue":"7","key":"10.1016\/j.urolonc.2020.07.020_bib0016","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.2215\/CJN.11941116","article-title":"Renal functional outcomes after surgery, ablation, and active surveillance of localized renal tumors: a systematic review and meta-analysis","volume":"12","author":"Patel","year":"2017","journal-title":"ClinJ Am Soc Nephrol"},{"key":"10.1016\/j.urolonc.2020.07.020_bib0017","doi-asserted-by":"crossref","first-page":"S27","DOI":"10.1016\/S1166-7087(16)30702-3","article-title":"Recommandations en onco-urologie 2016-2018 du CCAFU\u202f: cancer du rein","volume":"27","author":"Bensalah","year":"2016","journal-title":"Prog Urol"},{"issue":"4","key":"10.1016\/j.urolonc.2020.07.020_bib0018","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1007\/s00345-016-1913-4","article-title":"Partial nephrectomy versus ablative therapy for the treatment of renal tumors in an imperative setting","volume":"35","author":"Long","year":"2017","journal-title":"World J Urol"},{"issue":"1","key":"10.1016\/j.urolonc.2020.07.020_bib0019","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.juro.2008.03.030","article-title":"Feasibility and outcomes of repeat partial nephrectomy","volume":"180","author":"Johnson","year":"2008","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2020.07.020_bib0020","series-title":"7th International Symposium on VHL and Hereditary Kidney Cancers","article-title":"Health-related QOL in patients with von Hippel-Lindau disease is highly deteriorated after repetitive surgical treatments for VHL-related tumors in the CNS or visceral organ","author":"Shuin","year":"2006"},{"key":"10.1016\/j.urolonc.2020.07.020_bib0021","doi-asserted-by":"crossref","first-page":"S127","DOI":"10.1016\/S1769-7255(13)70042-7","article-title":"Survie et mortalit\u00e9 des patients en IRCT","volume":"9","author":"Chantrel","year":"2013","journal-title":"N\u00e9phrologie & Th\u00e9rapeutique"},{"issue":"3","key":"10.1016\/j.urolonc.2020.07.020_bib0022","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1007\/s10689-011-9440-3","article-title":"Management of renal tumors in Von Hippel-Lindau disease by percutaneous CT fluoroscopic guided radiofrequency ablation: preliminary results","volume":"10","author":"Iwamoto","year":"2011","journal-title":"Familial Cancer"},{"issue":"3","key":"10.1016\/j.urolonc.2020.07.020_bib0023","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1016\/S0022-5347(05)65279-2","article-title":"Percutaneous renal cryoablation of renal tumors in patients with von Hippel-Lindau disease","volume":"167","author":"Shingleton","year":"2002","journal-title":"J Urol"},{"issue":"5","key":"10.1016\/j.urolonc.2020.07.020_bib0024","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1016\/j.urolonc.2011.05.008","article-title":"Probe ablation as salvage therapy for renal tumors in von Hippel-Lindau patients: the cleveland clinic experience with 3 years follow-up","volume":"31","author":"Yang","year":"2013","journal-title":"Urol Oncol Semin Original Invest"},{"issue":"5","key":"10.1016\/j.urolonc.2020.07.020_bib0025","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1016\/j.juro.2010.01.022","article-title":"Percutaneous radio frequency ablation of renal tumors in patients with von Hippel-Lindau disease: preliminary results","volume":"183","author":"Park","year":"2010","journal-title":"J Urol"},{"issue":"15","key":"10.1016\/j.urolonc.2020.07.020_bib0026","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/j.purol.2017.08.007","article-title":"[Percutaneous renal ablation: Pre-, per-, post-interventional evaluation modalities and adapted management]","volume":"27","author":"Garnon","year":"2017","journal-title":"Prog Urol"}],"container-title":["Urologic Oncology: Seminars and Original Investigations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143920303434?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143920303434?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T10:19:06Z","timestamp":1761041946000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1078143920303434"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10]]},"references-count":26,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2020,10]]}},"alternative-id":["S1078143920303434"],"URL":"https:\/\/doi.org\/10.1016\/j.urolonc.2020.07.020","relation":{},"ISSN":["1078-1439"],"issn-type":[{"value":"1078-1439","type":"print"}],"subject":[],"published":{"date-parts":[[2020,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Repeat ablative therapy in hereditary or multifocal renal cancer: Functional and oncological outcomes","name":"articletitle","label":"Article Title"},{"value":"Urologic Oncology: Seminars and Original Investigations","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urolonc.2020.07.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}